These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 20723933)

  • 1. Citizenship in our profession.
    Droller MJ
    J Urol; 2010 Oct; 184(4):1248-50. PubMed ID: 20723933
    [No Abstract]   [Full Text] [Related]  

  • 2. Managed care considerations. A new era of advanced prostate cancer management.
    Muller R
    Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721
    [No Abstract]   [Full Text] [Related]  

  • 3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Nabhan C
    N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic cancer vaccine survives biotech bust.
    Ledford H
    Nature; 2015 Mar; 519(7541):17-8. PubMed ID: 25739610
    [No Abstract]   [Full Text] [Related]  

  • 5. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
    Chambers JD; Neumann PJ
    N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
    [No Abstract]   [Full Text] [Related]  

  • 6. Is Provenge Angst a symbol or symptom of the times?
    Holcombe DG
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274
    [No Abstract]   [Full Text] [Related]  

  • 7. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
    Gaines KK
    Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
    [No Abstract]   [Full Text] [Related]  

  • 8. Provenge approval means sensitive coverage decisions.
    Silverman E
    Manag Care; 2010 Sep; 19(9):31-4. PubMed ID: 20931888
    [No Abstract]   [Full Text] [Related]  

  • 9. Provenge: revolutionary technology or ethical bust?
    Dickerson JB
    Hum Vaccin; 2011 Apr; 7(4):477-80. PubMed ID: 21451262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prostate cancer 'vaccine' under development.
    Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancer.
    Brody H
    Nature; 2015 Dec; 528(7582):S117. PubMed ID: 26672779
    [No Abstract]   [Full Text] [Related]  

  • 12. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
    Becze E
    ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
    [No Abstract]   [Full Text] [Related]  

  • 13. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Sartor O
    BJU Int; 2012 Jul; 110(2 Pt 2):E105. PubMed ID: 22176510
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy: An immune one-two punch.
    Bourzac K
    Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous improvement versus innovation: the case for sipuleucel-T.
    Tombal B
    Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer.
    Klemm J; Mehr SR
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP119-21. PubMed ID: 22642277
    [No Abstract]   [Full Text] [Related]  

  • 17. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 18. The regulator disapproves.
    Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
    [No Abstract]   [Full Text] [Related]  

  • 19. Death threats for discrepancies over treatment data.
    Burton A
    Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668482
    [No Abstract]   [Full Text] [Related]  

  • 20. Fallout from flip-flops.
    Froese P
    Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.